Science in Society Archive

Science in Society #31 - Autumn 2006

The only radical science magazine on Earth

Science in Society 31 cover


From the Editors
Lessons from TGN1412
GM Free
Transgenic Maize with Monoclonal Antibodies Grown in France
USDA Proposes to Deregulate Its Own Transgenic Plum
GM Protein in Ice Cream
GM Egg Plant Contains Bt Toxin Linked to Hundreds of Allergy Cases and Thousands of Sheep Deaths
Save Our Oceans Save Our Planet
Oceans in Distress
Oceans and Global Warming
Oceans Carbon Sink or Source?
Shutting Down the Oceans Act I: Acid Oceans
Shutting Down the Oceans Act II: Abrupt Plankton Shifts
Shutting Down the Oceans Act III: Snuffing out the Green Fuse
Climate Change
Global Warming Is Happening
Technology Watch
Gene Therapy Nightmare for Mice: Could Humans be Next?
GM Probiotic Bacteria in Gene Therapy
Letters to the Editor
Parliament Launch of Which Energy?
Which Energy? Gets High Praise At Launch
I-SIS Energy Report Gets Cross Party Support
Nuclear Power: A Leap into the Dark Energy Chasm
The Slow Burning Fuse of Sustainability
How to be Food and Fuel Rich Under Climate Change
Recycling All Resources for Sustainability
Dream Farm 2 - Story So Far
Science and Government
FDA in Third World Drug Trial Scandals
FDA Under Fire for Corporate Links that Compromise Science
Beauty and the Beast - Flowers can Pollute

From the Editors

Lessons from TGN1412

It is five months since the catastrophic clinical trial of the drug TGN1412 in London. All six victims have survived so far, but their future is bleak. According to laboratory tests and medical reports seen by the International Herald Tribune, they have severely damaged immune systems and are likely to suffer immune problems for the rest of their lives. One is showing early signs of cancer.

This would be a tragic situation however it came about, but there is overwhelming evidence that it could and should have been avoided. Two major investigations and statements made by many scientists with experience in monoclonal antibody drugs have confirmed our initial suspicion that a cytokine storm, which caused the violent illnesses, was by no means totally unforeseeable as has been claimed (see London Drug Trial Catastrophe – Collapse of Science and Ethics; Warnings on FDA Approved Monoclonal Antibody Drugs; Post Mortem on the TGN1412 Disaster; Science in Society 30). It was a risk that ought to have been anticipated, and the body responsible for regulating drug trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has shown itself to have a dangerously limited view of its responsibilities.

In the light of what was known at the time of the drug trial, we need to ask some serious questions.

The role of the company that developed the drug

Why did TeGenero, the company that developed TGN1412, not realise this was a potentially hazardous trial and ensure that it was carried out under conditions that would reduce the risk to an acceptable level? There is nothing in the protocol for the trials or in the information given to the volunteers to suggest they did.

It’s not that they didn’t know about cytokine storms. On the contrary, they state on their website: “A pronounced T-cell activation and expansion mediated by CD28-SuperMAB(®) in animal models is accompanied by the expression of anti-inflammatory cytokines, like IL-10, rather than by the toxic cytokine storm of pro-inflammatory mediators induced by other agents that address the TCR complex.”

In other words, it is not at all unexpected that a drug of this kind should cause a cytokine storm. The special feature of CD28-SuperMAB is that it does not, at least not in the animals it was tested on. Like all monoclonal antibodies, however, it cannot be used in humans in its original form. It has to be genetically modified to make it immunologically acceptable to humans, which means that the drug used in the trial is inevitably different from the one that was tested on animals.

Thus, when the trials began, TGN1412 was known to be one of a class of drugs that can cause cytokine storms. The drug it was derived from did not do this in the animal tests and TGN1412 had not done it when tested in monkeys; if it had there would have been no question of testing it in humans. In the light of this, it is astonishing that TeGenero did not feel the need to be especially cautious, especially in view of the recognized species specificity of such drugs.

Parexel did not even follow the simple and relatively common practice of giving the drug to only one volunteer first and waiting long enough to see there were no untoward reactions before proceeding. And the doctors in the intensive care unit at Northwick Park have said that it was hours after the volunteers reached them before the Parexel team informed them of the possibility of a cytokine storm. Only then did they begin to treat their patients with high doses of steroids to blunt the immune response.

Other companies have been more prudent. In May this year, the BBC reported that Dr Harsukh Parmer, the Director of Discovery Medicines for AstraZeneca had said his company is also developing drugs of this kind. He had added that when working with monoclonal antibodies, the company carries out a wider range of tests than normal before proceeding to human trials. Even then, they begin by putting ultra low concentrations just under the skin, rather than straight into the blood stream.

The role of UK drug trials watchdog

What exactly is the role of the UK Watchdog MHRA (Medicines and Healthcare products Regulatory Agency)? In its investigation, it found no errors in the manufacture of the drug or in the way it was given to the trial participants. It concluded that, “an unpredicted biological action of the drug in humans is the most likely cause of the adverse reactions in the trial participants.” It said that the agreed protocol had been followed, but made no comment about whether the protocol had been appropriate for a trial of this sort of drug.

The MHRA does make some criticisms, but none that it considers material to the disastrous outcome. It found that Parexel, the company that carried out the trial, had failed to check that TeGenero’s insurance actually covered the volunteers. The MHRA does not, however, explain why it did not verify this as part of its approval of the protocol, as one would expect. The counter clerk at my local Post Office, for example, demands to see my third party liability insurance when I pay the annual tax on my car. In fact, the volunteers were insured but only for a total of £2 million, which may well be considerably less than the compensation they will be awarded. Someone should have checked this before the trial; nobody did.

Damning reports by Expert Scientific Group and by drug industry

There have been two substantial reports since that produced by the MHRA. One is by an Expert Scientific Group (ESG) set up by the UK Department of Health, and the other is by a joint task force of the UK BioIndustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI). These reports are comprehensive and damning, in complete contrast to that of the MHRA.

The BIA/ABPI report states:

“…there are sufficient signals in the publicly available data, and in historical precedents, to indicate that a very cautious approach is appropriate when assessing the risk, the starting dose and the study design with first-in-human studies with a potent agonist antibody such as TGN1412.”

What they are saying is that it was obvious to many scientists both in universities and in industry that special care is required in clinical trials using any drug like TGN1412.

The ESG report contains a list of 19 recommendations. Some, such as being far more careful in trials of novel drugs, are already “best”, if unfortunately not universal practice. They also recommend far more transparency and the sharing of information on the results of phase one clinical trials in general and Suspected Unexpected Serious Adverse Reactions (SUSARs) in particular.

Fragmentation of the pharmceutical industry a factor not considered

One factor not considered by these Reports is that the pharmaceutical industry, like other industries, has become fragmented. The major companies do not carry out all their research in house. Many new products originate in small firms and are only taken up by the big companies when they are past the early stages of development.

There are some advantages to this, but it has meant that the clinical trial of TGN1412 involved four companies: TeGenero, who developed it, Boehringer, who produced the samples used in the trial, Parexel, who conducted the trial, and an unnamed company that had carried out the trials on monkeys. As with the British railway system after privatisation, it appears there was no one with an overview of the entire process, no one with overall responsibility. Were the people at Parexel who designed the trial fully aware of the nature of the drug they were testing? If they were, they said nothing about it in the information they gave to the volunteers.

It also makes it harder for the victims to get adequate compensation. TeGenero has filed for insolvency; whereas a major pharmaceutical company would have the resources to pay whatever damages are awarded. Merck may be badly hurt by the Vioxx scandal but it is highly unlikely to go under.

A new regulatory body needed

As we write, six previously healthy young men are facing lifetimes of immune-related illness and the distinct possibility of early death. Despite what the experts in the field are saying, those responsible for the trials insist that they did everything properly, that what happened was completely unforeseeable. The regulatory body that should have intervened continues to back them up, also in the face of all the evidence.

The regulation of drug trials in the UK is clearly inadequate, and the problem is made worse as the pharmaceutical industry becomes increasingly international. The Food and Drug Administration in the USA is currently embroiled in several drug trial scandals amid widespread accusations of conflicts of interests in a high proportion of its scientific advisory panels (this issue). More and more trials are being carried out in third world countries where regulation is less stringent; Parexel, for example, is expanding its operations in Latin America.

The World Health Organisation is in the process of setting up an International Clinical Trials Registry so that the information from trials anywhere in the world can be accessed (WHO Registry of Clinical Trials, SiS30). There must also be internationally agreed standards for trials. And as a first step, the UK must get its own house in order.

The MHRA sees its task only as verifying that the right boxes have been ticked on a standard protocol, and it doesn’t do even that very well. After the incident, it had nothing to say beyond that what had happened had been unpredicted, when there is a consensus among the experts that it should have been anticipated.

Clinical trials are too important and potentially too hazardous to be regulated in such a casual manner. We need a new regulatory body with the scientific expertise to look critically and independently at all the trials that are submitted to it and the authority to reject any that do not satisfy the strict requirements.

Article first published 17/02/16

Got something to say about this page? Comment

Comment on this article

Comments may be published. All comments are moderated. Name and email details are required.

Email address:
Your comments:
Anti spam question:
How many legs on a spider?